NCT02288247 - A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone | Biotech Hunter

Enrollment

688

Participants

Timeline

Start Date

December 1, 2014

Primary Completion Date

April 30, 2020

Study Completion Date

March 15, 2024

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG

Enzalutamide

Oral

DRUG

Docetaxel

intravenous infusion

DRUG

Prednisolone

Oral

DRUG

Placebo

Oral

Trial Locations (89)

161

Site IT39004, Rome

1090

Site AT43001, Vienna

1340

Site BE32004, Ottignies

2820

Site BE32003, Bonheiden

3004

Site NO47005, Drammen

4000

Site BE32002, Liège

4010

Site AT43004, Linz

4011

Site NO47004, Stavanger

4615

Site NO47001, Kristiansand

6600

Site CH41005, Locarno

12808

Site CZ42001, Prague

14564

Site GR30003, Athens

20100

Site IT39003, Milan

22190

Site FR33004, Plérin

24903

Site RU70004, Obninsk

25126

Site IT39012, Brescia

27003

Site ES34005, Lugo

27100

Site IT39010, Pavia

28007

Site ES34003, Madrid

28040

Site ES34001, Madrid

28041

Site ES34002, Madrid

29000

Site FR33013, Quimper

29010

Site ES34007, Málaga

30008

Site ES34009, Murcia

30460

Site CZ42002, Plzeň -Lochotín

30625

Site DE49001, Hanover

34722

Site TR90003, Istanbul

35340

Site TR90002, Izmir

39008

Site ES34008, Santander

39185

Site SE46005, Kalmar

41013

Site ES34004, Seville

42103

Site DE49004, Wuppertal

46009

Site ES34006, Valencia

48149

Site DE49002, Münster

51056

Site FR33011, Reims

51465

Site DE49010, Bergisch Gladbach

52074

Site DE49008, Aachen

52100

Site IT39001, Arezzo

54007

Site GR30005, Thessaloniki

68167

Site DE49003, Mannheim

69120

Site DE49006, Heidelberg

70013

Site GR30001, Heraklion

71403

Site GR30004, Heraklion

72076

Site DE49015, Tübingen

72622

Site DE49018, Nürtingen

75014

Site FR33008, Paris

Site FR33014, Paris

77520

Site CZ42003, Olomouc

80131

Site IT39008, Naples

81000

Site FR33012, Albi

89075

Site DE49017, Ulm

92151

Site FR33005, Suresnes

105077

Site RU70002, Moscow

115478

Site RU70001, Moscow

125284

Site RU70003, Moscow

197022

Site RU70005, Saint Petersburg

197758

Site RU70006, Saint Petersburg

656 91

Site CZ42004, Brno

34298 cedex 5

Site FR33003, Montpellier

30907 cedex 2

Site FR33002, Nîmes

155 62

Site GR30006, Athens

00128

Site IT39005, Roma

05100

Site IT39002, Terni

1066 CX

Site NL31002, Amsterdam

1261 AN

Site NL31007, Blaricum

2134 TM

Site NL31004, Hoofddorp

3435 CM

Site NL31010, Nieuwegein

3045 PM

Site NL31003, Rotterdam

80-952

Site PL48004, Gdansk

31-501

Site PL48003, Krakow

93-513

Site PL48002, Lodz

02-507

Site PL48006, Warsaw

04-141

Site PL48005, Warsaw

Unknown

Site ES34010, Madrid

Site GB44014, Exeter

413 45

Site SE46002, Gothenburg

171 76

Site SE46003, Solna

751 85

Site SE46004, Uppsala

CH-8038

Site CH41009, Zurich

06500

Site TR90001, Ankara

AB25 2ZN

Site GB44010, Aberdeen

CB2 0QQ

Site GB44004, Cambridge

CF4 7XL

Site GB44018, Cardiff

SE1 9RT

Site GB44003, London

CH63 4JY

Site GB44007, Metropolitan Borough of Wirral

HA62RN

Site GB44020, Northwood

NR4 7UY

Site GB44015, Norwich

NG5 1PB

Site GB44002, Nottingham

SA2 8QA

Site GB44017, Swansea

All Listed Sponsors

collaborator

Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

INDUSTRY

lead

Astellas Pharma Europe Ltd.

INDUSTRY